ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Intra-Cellular Therapies, Inc. (ITCI) shows an Average True Range (ATR) of 0.35 and an Enterprise Value of 6.95B. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into ITCI's underlying financial health and market activity.
Intra-Cellular Therapies, Inc. (ITCI) technical indicators as of August 1, 2025: the SMA 20 is 0.28%, SMA 50 at 1.98%, and SMA 200 at 42.8%. The RSI 14 value is 84.55, suggesting its current momentum. These technical analysis signals help assess ITCI's price trends and potential future movements.
Intra-Cellular Therapies, Inc. (ITCI) stock performance overview as of August 1, 2025: The 52-week high is $131.98 (currently -0.08% below), and the 52-week low is $70.9 (currently 105.76% above). Over the past year, ITCI's performance is N/A, compared to the S&P 500's 14.84% change.
According to market data, Intra-Cellular Therapies, Inc. (ITCI) stock's recent performance metrics show that over the last month, ITCI is 0.45%, with a Year-to-Date (YTD) performance of 57.89%. Over the past year, the stock has seen a N/A change. These figures summarize ITCI's price movements across various periods, reflecting its historical returns.
According to current financial data, ITCI stock's P/E (TTM) ratio is -182.12, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for ITCI, including P/S (20.64), P/B (11.84), and P/FCF (-191.12), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.